Literature DB >> 1429362

Optimization of estrogen growth response in MCF-7 cells.

T E Wiese1, L G Kral, K E Dennis, W B Butler, S C Brooks.   

Abstract

The factors involved in estradiol-17 beta induced growth stimulation of MCF-7 human breast cancer cells have been examined. Wild type MCF-7 cells (and clone E3) were shown to undergo slow growth in phenol-red-free medium containing specific calf sera. The E3 clone was used to document a mean 6-day growth stimulation of 3.35-fold (doubling time = 33 +/- 3 h) in cultures supplemented with 10(-11) M estradiol-17 beta. The serum batch utilized in the culture medium is most important in acquiring significant growth stimulation of MCF-7 cells by estradiol-17 beta. Regardless of the absence of phenol-red, only selected sera (2 out of 14 tested) supported minimal growth of MCF-7 cells in the absence of added estradiol 17 beta (doubling time = 55 +/- 11 h). When a calf-serum-supplemented culture failed to display a complete growth response to estradiol-17 beta, it was due to the rapid growth of the cells in the control (minus estradiol-17 beta) flasks. Sera that promoted shorter doubling times for MCF-7 cells cultured in the absence of estradiol-17 beta were rendered less supportive of growth if treated with dextran-coated charcoal or when cultures were supplemented with the estrogen antagonist ICI 164,384 (10(-7) M). Pooled extracts of these sera were shown to contain stimulatory levels of estradiol-17 beta. Dextran-coated charcoal treatment of sera removed or deactivated factors (other than estradiol-17 beta) which were not only required for the growth of MCF-7 cells, but were necessary for estrogen-stimulated growth. Varying the serum-containing medium, buffer, and nutrient mix or the addition of insulin has no effect on the growth response of these cells to estradiol-17 beta. These investigations document the culture conditions required to produce a maximal and consistent proliferative effect of E2 on MCF-7 cells without exposing the serum constituent to damaging chemical or absorbent agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1429362     DOI: 10.1007/bf02631033

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  43 in total

1.  Model systems for the study of estrogen action in tissue culture.

Authors:  M Lippman; G Bolan; M Monaco; L Pinkus; L Engel
Journal:  J Steroid Biochem       Date:  1976 Nov-Dec       Impact factor: 4.292

2.  Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells.

Authors:  F E May; B R Westley
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

3.  Quantitative determination of nuclear estrogen receptors by an enzyme immunoassay: applicability and caveats.

Authors:  L G Kral; L M Doherty; S C Brooks
Journal:  J Steroid Biochem       Date:  1988-10       Impact factor: 4.292

4.  Estrogen response of MCF-7 cells grown on diverse substrates and in suspension culture: promotion of morphological heterogeneity, modulation of progestin receptor induction; cell-substrate interactions on collagen gels.

Authors:  N Pourreau-Schneider; Y Berthois; H Mittre; C Charpin; J Jacquemier; P M Martin
Journal:  J Steroid Biochem       Date:  1984-12       Impact factor: 4.292

5.  Evidence for a novel pituitary factor that potentiates the mitogenic effect of estrogen in human breast cancer cells.

Authors:  T C Dembinski; C K Leung; R P Shiu
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

6.  Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.

Authors:  K Seibert; S M Shafie; T J Triche; J J Whang-Peng; S J O'Brien; J H Toney; K K Huff; M E Lippman
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

7.  Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7.

Authors:  A M Brown; J M Jeltsch; M Roberts; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

8.  A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.

Authors:  P J Vickers; R B Dickson; R Shoemaker; K H Cowan
Journal:  Mol Endocrinol       Date:  1988-10

9.  A factor from plasma-derived human serum that inhibits the growth of the mammary cell line MCF-7: characterization and purification.

Authors:  M L Dell'Aquila; D A Pigott; D L Bonaquist; E V Gaffney
Journal:  J Natl Cancer Inst       Date:  1984-02       Impact factor: 13.506

10.  Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene.

Authors:  J F Savouret; A Bailly; M Misrahi; C Rauch; G Redeuilh; A Chauchereau; E Milgrom
Journal:  EMBO J       Date:  1991-07       Impact factor: 11.598

View more
  15 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

2.  BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.

Authors:  Crystal N Marconett; Travis J Morgenstern; Adrianna K San Roman; Shyam N Sundar; Ankur K Singhal; Gary L Firestone
Journal:  Cancer Biol Ther       Date:  2010-08-20       Impact factor: 4.742

3.  Estrogen mitogenic action. I. Demonstration of estrogen-dependent MTW9/PL2 carcinogen-induced rat mammary tumor cell growth in serum-supplemented culture and technical implications.

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

4.  Estrogen mitogenic action. ii. negative regulation of the steroid hormone-responsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications.

Authors:  D A Sirbasku; J E Moreno-Cuevas
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

Review 5.  Identification and assessment of endocrine disruptors: limitations of in vivo and in vitro assays.

Authors:  T Zacharewski
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

6.  Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6.

Authors:  M J Pilat; J K Christman; S C Brooks
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.

Authors:  Shyam N Sundar; Crystal N Marconett; Victor B Doan; Jamin A Willoughby; Gary L Firestone
Journal:  Carcinogenesis       Date:  2008-09-10       Impact factor: 4.944

8.  Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells.

Authors:  Andrei P Drabovich; Maria P Pavlou; Christina Schiza; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2016-04-11       Impact factor: 5.911

9.  Examination of the estrogenicity of 2,4,6,2',6'-pentachlorobiphenyl (PCB 104), its hydroxylated metabolite 2,4,6,2',6'-pentachloro-4-biphenylol (HO-PCB 104), and a further chlorinated derivative, 2,4,6,2',4',6'-hexachlorobiphenyl (PCB 155).

Authors:  M R Fielden; I Chen; B Chittim; S H Safe; T R Zacharewski
Journal:  Environ Health Perspect       Date:  1997-11       Impact factor: 9.031

10.  Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation.

Authors:  E Hollande; M Fanjul; N Houti; J C Faye; P Courriere
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.